|
Symbol |
Object Name |
Qualifiers
|
Evidence |
Notes |
Source |
PubMed Reference(s) |
RGD Reference(s) |
Position |
|
G
|
Abhd12
|
abhydrolase domain containing 12, lysophospholipase
|
decreases activity
|
ISO
|
orlistat results in decreased activity of ABHD12 protein
|
CTD |
PMID:18657971 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G
|
Abhd16a
|
abhydrolase domain containing 16A, phospholipase
|
decreases activity
|
ISO
|
orlistat results in decreased activity of ABHD16A protein
|
CTD |
PMID:18657971 |
|
NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
multiple interactions decreases expression
|
ISO
|
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Orlistat results in decreased expression of ACACA mRNA
|
CTD |
PMID:32347045 PMID:33476690 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457
|
|
G
|
Ache
|
acetylcholinesterase
|
decreases activity
|
ISO
|
Orlistat results in decreased activity of ACHE protein
|
CTD |
PMID:33844597 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G
|
Acot8
|
acyl-CoA thioesterase 8
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of ACOT8 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:153,531,193...153,542,851
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
multiple interactions
|
EXP ISO
|
orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]
|
CTD |
PMID:25087745 PMID:33476690 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]
|
CTD |
PMID:32045588 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
ISO
|
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]
|
CTD |
PMID:28721267 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G
|
Atf4
|
activating transcription factor 4
|
increases expression
|
ISO
|
orlistat results in increased expression of ATF4 mRNA
|
CTD |
PMID:17283163 |
|
NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:111,804,183...111,806,446
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in increased expression of BAX mRNA]
|
CTD |
PMID:32450208 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA]
|
CTD |
PMID:32450208 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G
|
Casp3
|
caspase 3
|
increases activity increases cleavage multiple interactions
|
ISO EXP
|
orlistat results in increased activity of CASP3 protein orlistat results in increased cleavage of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA]
|
CTD |
PMID:17283163 PMID:20805790 PMID:21723078 PMID:32450208 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO EXP
|
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA]
|
CTD |
PMID:18796435 PMID:20577697 PMID:32450208 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G
|
Casp9
|
caspase 9
|
increases activity multiple interactions
|
ISO EXP
|
orlistat results in increased activity of CASP9 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP9 mRNA]
|
CTD |
PMID:20805790 PMID:32450208 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G
|
Cat
|
catalase
|
multiple interactions decreases expression
|
EXP ISO
|
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein
|
CTD |
PMID:25087745 PMID:30667213 PMID:32450208 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G
|
Cck
|
cholecystokinin
|
multiple interactions decreases secretion
|
ISO
|
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] orlistat results in decreased secretion of CCK protein
|
CTD |
PMID:11408251 PMID:18303078 PMID:18647814 |
|
NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:121,153,500...121,160,084
|
|
G
|
Ccna2
|
cyclin A2
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of CCNA2 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:119,426,089...119,433,577
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression multiple interactions
|
ISO
|
Orlistat results in increased expression of CCND1 protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]
|
CTD |
PMID:30667213 PMID:32045588 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G
|
Ccne1
|
cyclin E1
|
increases expression
|
ISO
|
Orlistat results in increased expression of CCNE1 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101
|
|
G
|
Cd34
|
CD34 molecule
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]
|
CTD |
PMID:32045588 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G
|
Cdk1
|
cyclin-dependent kinase 1
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of CDK1 protein
|
CTD |
PMID:30667213 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,266,248...19,281,408
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of CDK2 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403
|
|
G
|
Cdk4
|
cyclin-dependent kinase 4
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of CDK4 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Orlistat results in increased expression of CDKN1A protein
|
CTD |
PMID:30667213 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
increases expression
|
ISO
|
orlistat results in increased expression of CDKN1B protein
|
CTD |
PMID:15138278 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
multiple interactions
|
ISO
|
Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
|
CTD |
PMID:33476690 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G
|
Cel
|
carboxyl ester lipase
|
decreases activity
|
ISO
|
orlistat results in decreased activity of CEL protein
|
CTD |
PMID:11592731 PMID:12381337 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G
|
Clps
|
colipase
|
multiple interactions
|
ISO
|
orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil]
|
CTD |
PMID:15158758 |
|
NCBI chr20:6,620,529...6,622,709
Ensembl chr20:6,620,529...6,622,689
|
|
G
|
Cpb2
|
carboxypeptidase B2
|
decreases expression
|
ISO
|
orlistat results in decreased expression of CPB2 protein
|
CTD |
PMID:16959692 |
|
NCBI chr15:56,967,128...57,015,964
Ensembl chr15:50,557,717...50,606,556
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of CPT1A protein
|
CTD |
PMID:30667213 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G
|
Cpt2
|
carnitine palmitoyltransferase 2
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of CPT2 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:122,664,677...122,682,095
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression
|
ISO
|
Orlistat results in increased expression of CYP3A4 mRNA; Orlistat results in increased expression of CYP3A4 protein
|
CTD |
PMID:20599501 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G
|
Dagla
|
diacylglycerol lipase, alpha
|
decreases activity
|
ISO
|
orlistat results in decreased activity of DAGLA protein
|
CTD |
PMID:16466961 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
orlistat results in increased expression of DDIT3 mRNA
|
CTD |
PMID:17283163 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
increases expression
|
ISO
|
orlistat results in increased expression of DDIT4 mRNA
|
CTD |
PMID:18796435 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:27,891,998...27,894,105
|
|
G
|
Eif2a
|
eukaryotic translation initiation factor 2A
|
increases phosphorylation multiple interactions
|
ISO
|
orlistat results in increased phosphorylation of EIF2A protein orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]
|
CTD |
PMID:17283163 PMID:20577697 |
|
NCBI chr 2:144,911,247...144,944,705
Ensembl chr 2:142,761,416...142,795,068
|
|
G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
increases response to substance multiple interactions
|
ISO
|
EIF2AK3 gene mutant form results in increased susceptibility to orlistat orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]
|
CTD |
PMID:17283163 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911
|
|
G
|
Eif4e
|
eukaryotic translation initiation factor 4E
|
increases phosphorylation
|
ISO
|
orlistat results in increased phosphorylation of EIF4E protein
|
CTD |
PMID:18796435 |
|
NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:227,066,673...227,098,683
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
affects response to substance decreases expression affects localization
|
ISO
|
ERBB2 protein affects the susceptibility to orlistat orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein orlistat affects the localization of ERBB2 protein
|
CTD |
PMID:15870086 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,411,313...83,435,078
|
|
G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
multiple interactions
|
ISO
|
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA]
|
CTD |
PMID:17283163 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,330,654...91,421,029
|
|
G
|
Etv4
|
ETS variant transcription factor 4
|
increases expression
|
ISO
|
orlistat results in increased expression of ETV4 protein
|
CTD |
PMID:15870086 |
|
NCBI chr10:87,206,977...87,222,202
Ensembl chr10:86,706,749...86,721,974
|
|
G
|
Fabp1
|
fatty acid binding protein 1
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of FABP1 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:103,191,006...103,194,788
|
|
G
|
Fas
|
Fas cell surface death receptor
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of FAS mRNA
|
CTD |
PMID:32347045 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G
|
Fasn
|
fatty acid synthase
|
affects binding affects response to substance multiple interactions decreases activity decreases expression
|
ISO
|
orlistat analog binds to FASN protein FASN protein affects the susceptibility to orlistat [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone] orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid] Orlistat results in decreased expression of FASN protein
|
CTD |
PMID:15026345 PMID:15138278 PMID:15870086 PMID:17012255 PMID:17618296 PMID:17847090 PMID:18281512 PMID:18710210 PMID:18723500 PMID:20148945 PMID:20577697 PMID:21213365 PMID:30667213 PMID:32045588 PMID:33476690 More...
|
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G
|
Gcg
|
glucagon
|
multiple interactions decreases expression decreases secretion
|
ISO
|
orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein] orlistat results in decreased expression of GCG protein orlistat results in decreased secretion of GCG protein
|
CTD |
PMID:12915676 PMID:18647814 PMID:19837920 |
|
NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:47,113,914...47,122,929
|
|
G
|
Ghrl
|
ghrelin and obestatin prepropeptide
|
multiple interactions
|
ISO
|
orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein]
|
CTD |
PMID:15998659 PMID:17138722 |
|
NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:146,865,712...146,869,621
|
|
G
|
Gip
|
gastric inhibitory polypeptide
|
decreases expression
|
ISO
|
orlistat results in decreased expression of GIP protein
|
CTD |
PMID:12915676 |
|
NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP
|
orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]
|
CTD |
PMID:29479035 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GPX1 mRNA]
|
CTD |
PMID:32450208 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G
|
Gpx8
|
glutathione peroxidase 8
|
increases expression
|
ISO
|
orlistat results in increased expression of GPX8 mRNA
|
CTD |
PMID:18796435 |
|
NCBI chr 2:46,409,646...46,413,401
Ensembl chr 2:44,676,454...44,680,195
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GSR protein]
|
CTD |
PMID:32450208 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G
|
Hba-a2
|
hemoglobin alpha, adult chain 2
|
decreases expression
|
ISO
|
orlistat results in decreased expression of HBA1 protein modified form
|
CTD |
PMID:19207292 PMID:19461584 |
|
NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,307,815...15,338,392 Ensembl chr10:15,307,815...15,338,392
|
|
G
|
Hmgcr
|
3-hydroxy-3-methylglutaryl-CoA reductase
|
multiple interactions
|
EXP
|
orlistat inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein]
|
CTD |
PMID:25087745 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression
|
ISO
|
orlistat results in increased expression of HSPA5 mRNA
|
CTD |
PMID:17283163 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G
|
Il10
|
interleukin 10
|
increases expression
|
EXP
|
Orlistat results in increased expression of IL10 mRNA
|
CTD |
PMID:32450208 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA]
|
CTD |
PMID:32450208 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]
|
CTD |
PMID:21088047 PMID:32045588 PMID:32735172 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in increased expression of INS1 protein]
|
CTD |
PMID:25087745 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G
|
Ins2
|
insulin 2
|
decreases expression increases expression affects expression multiple interactions
|
ISO
|
orlistat results in decreased expression of INS protein orlistat results in increased expression of INS protein orlistat affects the expression of INS protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
|
CTD |
PMID:10095983 PMID:11274935 PMID:12915676 PMID:33476690 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:197,843,281...197,864,775
|
|
G
|
Kdelr3
|
KDEL endoplasmic reticulum protein retention receptor 3
|
increases expression
|
ISO
|
orlistat results in increased expression of KDELR3 mRNA
|
CTD |
PMID:18796435 |
|
NCBI chr 7:112,959,632...112,969,858
Ensembl chr 7:111,079,218...111,101,600
|
|
G
|
Kdr
|
kinase insert domain receptor
|
decreases expression
|
ISO
|
orlistat results in decreased expression of KDR protein
|
CTD |
PMID:17012255 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,217,871...32,261,018
|
|
G
|
Krt81
|
keratin 81
|
increases expression
|
ISO
|
orlistat results in increased expression of KRT81 mRNA
|
CTD |
PMID:18796435 |
|
NCBI chr 7:132,577,112...132,582,238
Ensembl chr 7:132,576,492...132,582,170
|
|
G
|
Lcat
|
lecithin cholesterol acyltransferase
|
multiple interactions
|
EXP
|
orlistat inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein]
|
CTD |
PMID:25087745 |
|
NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231
|
|
G
|
Lep
|
leptin
|
multiple interactions
|
ISO EXP
|
orlistat inhibits the reaction [Dietary Fats results in increased expression of LEP protein]
|
CTD |
PMID:21332399 PMID:25087745 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G
|
Lipf
|
lipase F, gastric type
|
decreases activity
|
ISO
|
orlistat results in decreased activity of LIPF protein
|
CTD |
PMID:11408251 PMID:12381337 |
|
NCBI chr 1:231,493,498...231,511,845
Ensembl chr 1:231,493,498...231,511,845
|
|
G
|
Lpl
|
lipoprotein lipase
|
decreases activity multiple interactions
|
ISO EXP
|
orlistat results in decreased activity of LPL protein orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein] [orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides
|
CTD |
PMID:12388125 PMID:12573449 PMID:15910848 PMID:15994321 PMID:18698144 PMID:25087745 More...
|
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:32045588 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:32045588 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G
|
Met
|
MET proto-oncogene, receptor tyrosine kinase
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]
|
CTD |
PMID:32045588 |
|
NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:45,790,791...45,897,876
|
|
G
|
Napepld
|
N-acyl phosphatidylethanolamine phospholipase D
|
decreases activity
|
EXP
|
orlistat results in decreased activity of NAPEPLD protein
|
CTD |
PMID:16466961 |
|
NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
EXP ISO
|
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
|
CTD |
PMID:32450208 PMID:33476690 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein]
|
CTD |
PMID:32450208 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G
|
Npy
|
neuropeptide Y
|
increases expression
|
ISO
|
orlistat results in increased expression of NPY protein
|
CTD |
PMID:15962606 |
|
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:78,881,264...78,888,495
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
increases activity
|
ISO
|
orlistat results in increased activity of NR1I2 protein
|
CTD |
PMID:20599501 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
multiple interactions
|
ISO
|
Orlistat binds to and results in increased activity of NR1I3 protein alternative form
|
CTD |
PMID:31312845 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G
|
Nts
|
neurotensin
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein]
|
CTD |
PMID:18303078 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO
|
[orlistat co-treated with Thapsigargin] results in increased cleavage of PARP1 protein orlistat results in increased cleavage of PARP1 protein
|
CTD |
PMID:15870086 PMID:17283163 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]
|
CTD |
PMID:32045588 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G
|
Pla2g7
|
phospholipase A2 group VII
|
decreases activity multiple interactions
|
ISO
|
orlistat results in decreased activity of PLA2G7 protein [orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein
|
CTD |
PMID:16911813 PMID:18513463 PMID:18657971 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G
|
Pnlip
|
pancreatic lipase
|
decreases secretion decreases activity multiple interactions affects folding
|
ISO EXP
|
orlistat results in decreased secretion of PNLIP protein orlistat results in decreased activity of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] orlistat affects the folding of PNLIP protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil]
|
CTD |
PMID:11408251 PMID:11668201 PMID:12381337 PMID:15158758 PMID:19346257 |
|
NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654
|
|
G
|
Pnliprp2
|
pancreatic lipase related protein 2
|
decreases activity
|
ISO EXP
|
orlistat results in decreased activity of PNLIPRP2 protein Orlistat results in decreased activity of PNLIPRP2 protein
|
CTD |
PMID:9822688 PMID:17401110 |
|
NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
|
|
G
|
Pon1
|
paraoxonase 1
|
increases activity
|
ISO
|
orlistat results in increased activity of PON1 protein
|
CTD |
PMID:11820148 PMID:17134960 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:33,294,722...33,321,360
|
|
G
|
Ppard
|
peroxisome proliferator-activated receptor delta
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]
|
CTD |
PMID:33476690 |
|
NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,298,785...6,363,968
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
increases expression
|
ISO
|
Orlistat results in increased expression of PPARG mRNA
|
CTD |
PMID:32347045 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G
|
Ppt1
|
palmitoyl-protein thioesterase 1
|
decreases expression
|
ISO
|
Orlistat results in decreased expression of PPT1 protein
|
CTD |
PMID:30667213 |
|
NCBI chr 5:140,406,318...140,427,201
Ensembl chr 5:135,121,163...135,142,048
|
|
G
|
Ppy
|
pancreatic polypeptide
|
multiple interactions
|
ISO
|
orlistat inhibits the reaction [Triglycerides results in increased secretion of PPY protein]
|
CTD |
PMID:15998659 |
|
NCBI chr10:87,054,747...87,056,044
Ensembl chr10:87,054,756...87,055,455
|
|
G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
multiple interactions
|
EXP ISO
|
orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein]
|
CTD |
PMID:18390901 PMID:19167487 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
increases expression multiple interactions
|
ISO
|
Orlistat results in increased expression of PTEN protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]
|
CTD |
PMID:32045588 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]
|
CTD |
PMID:32045588 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G
|
Pyy
|
peptide YY
|
decreases secretion multiple interactions
|
ISO
|
orlistat results in decreased secretion of PYY protein orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein]
|
CTD |
PMID:15998659 PMID:17138722 PMID:18647814 |
|
NCBI chr10:87,561,347...87,562,470
Ensembl chr10:87,061,161...87,061,815
|
|
G
|
Rb1
|
RB transcriptional corepressor 1
|
decreases phosphorylation
|
ISO
|
orlistat results in decreased phosphorylation of RB1 protein
|
CTD |
PMID:15138278 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in increased expression of RELA mRNA]
|
CTD |
PMID:32450208 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G
|
Rps6
|
ribosomal protein S6
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]
|
CTD |
PMID:32045588 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G
|
Sec24d
|
SEC24 homolog D, COPII coat complex component
|
increases expression
|
ISO
|
orlistat results in increased expression of SEC24D mRNA
|
CTD |
PMID:18796435 |
|
NCBI chr 2:211,418,557...211,526,588
Ensembl chr 2:211,418,623...211,526,587
|
|
G
|
Skp2
|
S-phase kinase associated protein 2
|
multiple interactions decreases expression
|
ISO
|
[orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein orlistat results in decreased expression of SKP2 protein
|
CTD |
PMID:15138278 |
|
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
orlistat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:48,121,061...48,163,268
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
multiple interactions decreases expression
|
ISO
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein] Orlistat results in decreased expression of SREBF1 protein
|
CTD |
PMID:32045588 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G
|
Tf
|
transferrin
|
multiple interactions
|
ISO
|
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
|
CTD |
PMID:33476690 |
|
NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:103,767,995...103,816,511
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA
|
CTD |
PMID:33476690 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [Dietary Fats results in increased expression of TLR4 protein]
|
CTD |
PMID:32735172 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF protein]
|
CTD |
PMID:15994321 PMID:32045588 PMID:32450208 PMID:32735172 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G
|
Tnfsf10
|
TNF superfamily member 10
|
increases response to substance
|
ISO
|
orlistat results in increased susceptibility to TNFSF10 protein
|
CTD |
PMID:18796435 PMID:21406729 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
EXP
|
Orlistat inhibits the reaction [Dietary Fats results in increased expression of TP53 mRNA]
|
CTD |
PMID:32450208 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G
|
Ucp1
|
uncoupling protein 1
|
multiple interactions
|
ISO
|
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
|
CTD |
PMID:33476690 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:24,808,783...24,816,852
|
|
G
|
Xbp1
|
X-box binding protein 1
|
multiple interactions
|
ISO
|
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA]
|
CTD |
PMID:17283163 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693
|
|